Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.77
-5.9%
$1.74
$1.41
$5.01
$10.40M1.1926,754 shs51,533 shs
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
$7.81
$7.81
$4.06
$9.16
N/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
$3.46
+2.4%
$3.73
$2.95
$13.60
$198.04M2.16732,079 shs784,232 shs
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$8.62
+2.1%
$7.85
$5.67
$30.60
$139.57M-0.09165,065 shs73,324 shs
Vectura Group plc stock logo
VEGPF
Vectura Group
$1.77
$1.77
$1.64
$2.74
$1.07B0.372,185 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-5.85%+1.14%-4.84%+14.19%-55.19%
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
+2.37%+8.09%-10.82%-48.59%-14.57%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
+2.13%+6.09%-9.45%+24.78%-67.93%
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.559 of 5 stars
3.54.00.00.00.00.81.3
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
3.3055 of 5 stars
3.40.00.04.40.01.70.6
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
4.4177 of 5 stars
3.13.00.04.23.21.71.3
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50775.71% Upside
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00420.23% Upside
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.17
Hold$19.80129.70% Upside
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OMER, VEGPF, RAPT, APRE, and EMIS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/26/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$48.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.50M6.53N/AN/A$3.55 per share0.50
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M93.19N/AN/A$11.51 per share0.75
Vectura Group plc stock logo
VEGPF
Vectura Group
$244.76M4.37$0.28 per share6.33$1.16 per share1.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)
Vectura Group plc stock logo
VEGPF
Vectura Group
$157.16M$0.266.8117.70N/AN/AN/AN/AN/A

Latest OMER, VEGPF, RAPT, APRE, and EMIS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/8/2025Q1 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$2.48-$0.64+$1.84-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.90
5.90
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
21.11
21.11
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
N/A
Omeros Corporation stock logo
OMER
Omeros
48.79%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%
Vectura Group plc stock logo
VEGPF
Vectura Group
N/A

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
13.63%
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
72.90%
Omeros Corporation stock logo
OMER
Omeros
12.90%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.36%
Vectura Group plc stock logo
VEGPF
Vectura Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.78 millionNo Data
Emisphere Technologies Inc. stock logo
EMIS
Emisphere Technologies
6N/AN/ANot Optionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million16.15 millionOptionable
Vectura Group plc stock logo
VEGPF
Vectura Group
502604.26 millionN/ANot Optionable

Recent News About These Companies

Vectura and Hikma to develop US asthma generic
European Stocks See Mixed Session as U.K.'s FTSE Leads
VECTURA GROUP LS -,000271 (V4TA.BE)
Vectura Group PLC (V4TA.BE)
Results for 'Vectura-Fertin Pharma'
Vectura Group (OTC:VEGPF), Short Interest Report
Carlyle stays in race for Vectura
Form 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.80 -0.08 (-4.26%)
As of 07/10/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Emisphere Technologies stock logo

Emisphere Technologies OTCMKTS:EMIS

$7.81 0.00 (0.00%)
As of 12/9/2020

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Omeros stock logo

Omeros NASDAQ:OMER

$3.46 +0.08 (+2.37%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$3.45 -0.01 (-0.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$8.62 +0.18 (+2.13%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$8.62 0.00 (-0.06%)
As of 07/10/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Vectura Group stock logo

Vectura Group OTCMKTS:VEGPF

$1.77 0.00 (0.00%)
As of 11/1/2021

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.